Dr. Reddy’s to Buy Generics From Allergan, Teva for $350 Million

Dr. Reddy’s Laboratories Ltd. agreed to buy a handful of generic products, most of them awaiting U.S. regulatory approval, from Teva Pharmaceutical Industries Ltd. and a unit of Allergan Plc, a transaction required for Teva to be allowed to proceed with the takeover of Allergan’s generics business.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.